Patent 10206932 was granted and assigned to TherapeuticsMD on February, 2019 by the United States Patent and Trademark Office.
Pharmaceutical compositions for co-administering estradiol and progesterone to a human subject in need thereof are provided. In some embodiments, the pharmaceutical composition comprises solubilized estradiol, suspended progesterone, and a solubilizing agent comprising a medium chain (C6-C12) oil.